Cannabis médical et récréatif


#21

Liste des producteurs de cannabis à des fins médicales autorisés approuvés au Canada
http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/list-fra.php


#22

UMB.c halted pending news ! :slight_smile:


#23

http://cawidgets.morningstar.ca/ArticleTemplate/ArticleGL.aspx?s=Acquire&r=TheNewsWire_20170705AD4FKx03&culture=en-CA&IdType=CS&Id=CAN%3AUMB&MaxCount=10&popup=true&_=1499276803371


#24

encore mieux!
http://cawidgets.morningstar.ca/ArticleTemplate/ArticleGL.aspx?s=Acquire&r=TheNewsWire_20170706knDFe0J6&culture=en-CA&IdType=CS&Id=CAN%3AUMB&MaxCount=10&popup=true&_=1499355397928


#25

Belle innovation de tHCX!

http://cawidgets.morningstar.ca/ArticleTemplate/ArticleGL.aspx?s=Acquire&r=MWR_urn:newsml:marketwired.com:20020408:2017072511G143172-002_CAN&culture=en-CA&IdType=CS&Id=CAN%3ATHCX&MaxCount=10&popup=true&_=1500998040064


#26

$UMB.c gardez le sur la watchlist…il est sur le bord du breakout et la licence est proche d’après moi


#27

BOOM

Vancouver, B.C. / TheNewswire / August 8, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“ Umbral or Company ”) is pleased to announce that its 75% owned subsidiary, PhyeinMed Inc. (“PhyeinMed”) a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) has signed an agreement with Canopy Growth Corporation (TSX:WEED) (“Canopy Growth”) to supply cannabis products via the CraftGrow line on Tweed Main Street’s online store.

Pending receiving a licence to cultivate and sell cannabis products from Health Canada, PhyeinMed stands to substantially accelerate its speed to market through joining the CraftGrow program and leveraging their marketing and distribution network. Canopy is widely recognized as leading the way in the Canadian cannabis market, and has a global reputation for providing top quality products and partnering with other top producers. This partnership also allows PhyeinMed to significantly reduce market acquisition costs for infrastructure, while driving early revenue through Tweed Main Street’s online store.

Mark Zekulin , President of Canopy Growth, has previously commented regarding the CraftGrow opportunity, “Our approach with CraftGrow and Tweed Main Street is to establish a diverse online marketplace for legal medical cannabis products. People can seamlessly access Canada’s leading cannabis brands with one medical document rather than being tied to a single producer. For new producers, having access to the largest group of registered patients in the country can go a long way towards building brand awareness. And for us, it’s an opportunity to position ourselves as the online source of cannabis in Canada , while bringing more product variety and reliability to our customers."

PhyeinMed is pleased by recent developments and conversations confirming that Health Canada has streamlined licensing in order to move applicants through the process more effectively. These efforts have created a more open discussion between PhyeinMed and the Offices of Medical Cannabis reducing the uncertainty as to the administrative steps required to obtain a production license.

“Our collaborative agreement with Canopy Growth is a major milestone for us.” states PhyeinMed CEO, Debra Senge r, “As a late stage applicant we recognize the need to optimize our exposure and brand awareness, and by utilizing Canopy Growth’s Tweed Main Street it gives us access to a large consumer base in an expanding medical cannabis market. We intend to offer high quality products which we believe will be popular with the substantial customer base Canopy has established. This agreement gives us a true partner in the industry and will expose us to industry leading expertise, knowledge and best practices. These learnings will be very valuable to PhyeinMed as we progress through the final steps of licensing. We are very pleased to be working with such a global leader in the cannabis space .”

Read more at http://www.stockhouse.com/news/press-releases/2017/08/08/umbral-s-subsidiary-phyeinmed-joins-the-canopy-grow-family#HA87cg4TLHPVo1xO.99


#28

J’espère vraiment que tout le monde a acheté du UMB. Les prochaines nouvelles vont propoulser le titre


#29

propulser plus ou moins haut que Mezzi ?


#32

si tu peux te tromper sur seulement 1 titre sur 10, tu vas bien te débrouiller en bourse !


#36

Citation de mon post du 1er Janvier 2016

Un 4x bagger jusqu’à maintenant :wink:

Un autre que j’avais callé en 2015, SL.c à 0.15$ ( devenu FIRE.v ), Il est monté à 2$ pour un 10x+ bagger avant de revenir autour de 1.20$ présentement

@Luc Rendu à 22$ :wink:

un petit dernier pour toi @Luc

KEK.v devenu PEEK.v est finalement monté jusqu’à 2.39$ pour un 8x bagger avant de se replier

et j’oubliais bien sûr:

DYA.v a touché 1.18$ pour un 12x bagger avant de se replier

Évidemment plusieurs autres titres que j’ai choisi n’ont pas fait grand chose ( du sur place ) et une petite minorité a pris une débandade tel que MZI.v


#37

Quand tu vas nous faire des calls de 10 baggers, tu pourras te permettre d’être sarcastique sur le 1 titre que j’ai mal callé.


#38

Les pièces du puzzle se placent

Umbral Energy completes PhyeinMed interest acquisition

2017-08-21 10:07 ET - News Release

Mr. Jag Bal reports

UMBRAL COMPLETES ACQUISITION OF ADDITIONAL 25% INTEREST IN LATE STAGE ACMPR APPLICANT PHYEINMED AND ADOPTION OF RESTRICTED SHARE UNIT PLAN

Further to its press release dated July 5, 2017, and pursuant to a share purchase agreement dated effective June 21, 2017, among Umbral, its wholly owned subsidiary 1005477 B.C. Ltd., Estek Ventures Corp. and Debra Senger, Umbral Energy Corp. has acquired an additional 25-per-cent interest in PhyeinMed Inc., a late-stage Health Canada access to cannabis for medical purposes regulations applicant for the purpose of growing, selling and distributing medical cannabis. The company now owns 75 per cent of the issued and outstanding common shares of PhyeinMed while the vendor retains a 25-per-cent interest.

In consideration for the acquisition and pursuant to the terms of the SPA, the company has:

Paid a total of $100,000 (an additional $20,000 will be paid upon completion by the company of equity financing(s) that have raised gross proceeds of at least $1.5-million);
Issued seven million common shares in the capital of the company at closing. Such shares are subject to a four-month hold period under applicable securities laws expiring on Dec. 19, 2017, and are also subject to a voluntary escrow period pursuant to which 10 per cent of the shares were released immediately and an additional 15 per cent of the shares will be released every six months from the closing date;
Will issue an additional four million shares upon final award of an ACMPR production licence;
Granted two million stock options to Senger to acquire up to two million shares at an exercise price of 10 cents per share (see press release dated Aug. 16, 2017);
Awarded to Senger 2.4 million restricted stock units to Senger and an additional 1.6 million restricted share units to other eligible recipients;
Committed up to an additional $3-million to finance PhyeinMed’s efforts in the medical marijuana business.
In order to formalize a pay-for-performance culture and further strengthen the alignment between company insiders with shareholders of the company, Umbral also announces that a restricted share unit plan for directors, executive officers, employees and consultants of the company was approved by the board and is expected to be put forth for ratification by the company’s shareholders at the next annual general meeting of shareholders. As detailed above, four million restricted share units were awarded in connection with the acquisition which can be settled for shares on a one-for-one basis. Half of the RSUs vest immediately while the remaining RSUs vest in 12 months. All RSUs awarded expire on Aug. 18, 2022.

Further details regarding the RSU plan and the awards made under such plan will be set out in the management information circular of the company in connection with the next AGM.

Further to the news release dated July 14, 2017, the non-brokered private placement consisting of 34 million units at a purchase price of six cents per unit is expected to close Aug. 23, 2017, oversubscribed.


#39

J’ai participé au PP et je m’attends à un 10 bagger. Faites vos devoirs


#40

News out, grosse demande pour le PP :slight_smile:

Umbral Announces Increase To Private Placement Due To Significant Interest
C.UMB | 1 hour ago
(TheNewswire)

Vancouver, B.C., August 24, 2017 / TheNewswire / UMBRAL ENERGY CORP. (CSE: UMB) (the “ Company ” or “ Umbral ”) is pleased to announce that due to investor demand, it is increasing the maximum amount to be raised under its previously announced non-brokered private placement of units to $2,622,000 (the “ Offering ”).

The Offering will now consist of the sale of up to 43,700,000 units (the “ Units ”) at a purchase price of $0.06 per Unit with each unit consisting of one common share in the capital of the Company (a “ Share ”) and one share purchase warrant (a “ Warrant ”). Each full warrant will entitle the holder to purchase one additional Share for a period of 2 years from the closing date, at a purchase price of $0.10 per Share.

The Offering is expected to close on or about August 28, 2017. Please see the Company’s press release dated July 14, 2017 for further details regarding the Offering.


#41

THC.c vient d’avoir sa license de vente. L’action a pris un saut de 90% sur 7M de volume. L’application a été dirigée par Zena Prokosh qui travaille maintenant avec PhyeinMed ( UMB.c ). C’est de bonne augure


#42

$UMB.c est en breakout, sur le point de fermer à son plus haut niveau depuis 5 ans ! C’est un signal extrêmement bullish d’un point de vue technique

Edit: L’action a effectivement fermé à son plus haut des 5 dernières années au haut du jour sur fort volume. à suivre…


#43

Got in @ 0,10199$ pour une micro position. GL!


#44

Bravo, tu ne seras pas déçu selon moi !


#45

Le PP devrait fermer de facon imminente. Le stock pour sa part s’envole !